Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.
Journal: Neuro-oncology advances
Published: November 03, 2021
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Journal: British journal of haematology
Published: July 06, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: November 16, 2016
Evaluating imbalances of adverse events during biosimilar development.
Journal: mAbs
Published: April 07, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Journal: British journal of haematology
Published: January 06, 2016
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 09, 2015
A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).
Journal: British journal of clinical pharmacology
Published: February 21, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026